An open label, dose escalation study to evaluate safety, tolerability, and pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) [OCX 0191] in cancer patients using a single daily dose for five days

Trial Profile

An open label, dose escalation study to evaluate safety, tolerability, and pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) [OCX 0191] in cancer patients using a single daily dose for five days

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jul 2013

At a glance

  • Drugs OCX 191 (Primary)
  • Indications Breast cancer; Colorectal cancer; Lung cancer; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 27 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top